Meeting
2011 ASCO Annual Meeting
Utilization and clinical practice impact of an interactive tool for guiding choice of systemic adjuvant treatment (adj TX) for patients with early breast cancer (EBC).
Authors
P. Ravdin
University of Texas M. D. Anderson Cancer Center, Houston, TX
P. Ravdin , S. Martino , M. D. Pegram , N. J. Robert , S. M. Swain , D. Janssen , A. Bowser , J. A. Mortimer , R. W. Carlson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research
Track
Health Services Research
Sub Track
Outcomes Research
Citation
J Clin Oncol 29: 2011 (suppl; abstr 6063)
Abstract #
6063
Poster Bd #
43C
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Estrogen receptor in HER2-positive early breast cancer: Two different diseases?
First Author: Eva Maria Ciruelos Gil
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2022 ASCO Annual Meeting
Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.
First Author: Maria Vittoria Dieci
Poster
2018 ASCO Annual Meeting
Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients: Randomized controlled trial (RESPECT).
First Author: Masataka Sawaki